JSJun Suzuki

Jun Suzuki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jun Suzuki has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Plasmid-encoded FRI-10 carbapenemase harboured by non- Enterobacter species isolated from a wastewater sample in Tokyo, Japan

    by Kou Murakami, Miki Ida, Yasunori Suzuki, Makiko Kobayashi, Noriko Konishi, Rei Kato, Tsukasa Ariyoshi, Kai Kobayashi, Morika Mitobe, Hiroaki Kubota, et al.

  • Open Access

    Detection of myxosporean parasites in human fecal samples associated with foodborne illness

    by Yukihiro Kodo, Rie Murata, Jun Suzuki, Kohji Mori, Takashi Chiba

    In 2011, Kudoa septempunctata was recognized as a causative agent of foodborne illness in Japan. Since then, studies have conducted surveillance for this parasite in flounder, a primary source of diarrhea and vomiting, and have reported the detection of K. septempunctata in fecal samples from patients. Although sporadic diarrheal cases suspected to be associated with the consumption of fish other than flounder have also been reported, information regarding the examination of patient feces or leftover fish in such cases remains limited. In this study, we investigated the detection of Kudoa and Unicapsula genes in patient fecal samples and the presence of myxosporean parasites in fish associated with diarrheal cases following the consumption of raw fish. Among 143 fecal samples analyzed, Kudoa and Unicapsula genes were detected in 23.1%, with the highest detection rate observed in Kudoa hexapunctata cases. The fecal detection rate was significantly higher when samples were collected within four days after fish consumption, particularly in cases involving K. hexapunctata and Unicapsula seriolae, while detection rate declined in samples collected after five days. Myxosporean parasites were identified in 85.7% of leftover fish samples, whereas fish from another batch prepared at the same facilities consistently tested negative. The higher fecal detection rate observed in K. hexapunctata cases may reflect greater spore ingestion, likely due to larger consumption volumes of tuna. These findings emphasize the importance of timely investigations and testing of fecal samples within four days of consumption and leftover fish samples in suspected myxosporean diarrhea outbreaks.

  • Differential Copy Number of Chromosomal blaCTX−M−14 in Escherichia coli Sequence Type ST38 from Companion Dogs and Cats

    by Kai Kobayashi, Hiroaki Kubota, Tsukasa Ariyoshi, Yasunori Suzuki, Kohji Mori, Jun Suzuki, Yoshitsugu Ochiai, Kenji Sadamasu, Takashi Chiba


  • Open Access

    Multiplex amplicon sequencing for the comprehensive genotyping of Mycoplasma pneumoniae

    by Hiroaki Kubota, Rumi Okuno, Tsuyoshi Kenri, Yumi Uchitani, Tsukasa Ariyoshi, Isao Yoshida, Kai Kobayashi, Morika Mitobe, Jun Suzuki, Kenji Sadamasu

    Major genotyping methods used to characterize Mycoplasma pneumoniae strains are based on various experimental approaches that need to be implemented in parallel for each strain. In this study, we developed a comprehensive workflow based on amplicon sequencing using next-generation sequencing. This workflow comprised PCR amplification with seven tubes, collection into single tubes, shotgun sequencing, de novo assembly separating each target into individual contigs, and in silico genotyping. The results for p1 , orf6 , multilocus sequence types, 23S ribosomal RNA gene mutations conferring macrolide resistance, and single-nucleotide polymorphisms identifying the p1 type 1 lineage were obtained simultaneously. The genotyping accuracy was confirmed by comparing the sequences with the whole-genome sequences of 40 M . pneumoniae isolates collected in Tokyo, Japan. The workflow described not only enables high-throughput comprehensive data collection but also enables the detection of novel genotypes with single-nucleotide resolution. IMPORTANCE: Genotyping plays a central role in the molecular epidemiology of pathogenic bacteria, and many methods have been developed to identify prevalent lineages, infection routes, and antimicrobial resistance. Whole-genome sequencing generally provides most of the genetic information targeted by classic PCR-based schemes and has contributed to the construction of a simplified workflow for many bacterial species. However, several issues concerning the Mycoplasma pneumoniae genome, such as the presence of repetitive elements of the p1 gene, prevent the collection of genotyping results from a single run of short-read shotgun sequencing. Herein, we describe a simplified workflow using amplicon sequencing that covers most of the major genotyping schemes for M. pneumoniae , including p1 genotyping. The workflow effectively characterized M. pneumoniae clinical isolates. This workflow could help advance research on the molecular epidemiology of M. pneumoniae and the detection of novel genotypes.


  • Open Access

    Sitafloxacin- Versus Moxifloxacin-Based Sequential Treatment for Mycoplasma Genitalium Infections: Protocol for a Multicenter, Open-Label Randomized Controlled Trial

    by Naokatsu Ando, Daisuke Mizushima, Yosuke Shimizu, Yukari Uemura, Misao Takano, Morika Mitobe, Kai Kobayashi, Hiroaki Kubota, Hirofumi Miyake, Jun Suzuki, et al.

    Background: Mycoplasma genitalium is an emerging sexually transmitted pathogen associated with increasing antibiotic resistance. The current treatment guidelines recommend moxifloxacin-sequential therapy for macrolide-resistant Mgenitalium or strains with unknown resistance profiles. However, it is unclear whether sitafloxacin, a 4th-generation fluoroquinolone antibiotic, is effective against resistant strains. Objective: This study aims to assess and compare the efficacy and safety of sitafloxacin- and moxifloxacin-based treatment regimens for managing Mgenitalium infections. Methods: We will conduct this randomized controlled trial at multiple centers in Japan. Eligible participants include adults aged 18 years or older with a confirmed Mgenitalium infection, as determined through the nucleic acid amplification test. Patients will be randomly assigned using a stratified approach based on the treatment facility and infection site. The interventions comprise oral sitafloxacin (200 mg) daily for 7 days (with optional pretreatment of oral doxycycline, 200 mg, daily for up to 7 days), with a control group receiving oral doxycycline (200 mg) daily for 7 days followed by moxifloxacin (400 mg) daily for another 7 days. The primary outcome is the treatment success rate with a superiority margin of 10%, as confirmed through the nucleic acid amplification test. Secondary outcomes encompass changes in the bacterial load at the urogenital or rectal sites and the emergence of posttreatment-resistant mutant strains. Results: Enrollment commenced in June 2023 and will conclude in December 2024, with findings anticipated by 2025. The expected success rates fall within the range of 80% for sitafloxacin and 42% for moxifloxacin against Mgenitalium carrying the G248T (S83I) mutation, based on previous studies. Accordingly, with a 5% significance level (2-sided) and 80% statistical power, we aim to recruit 50 participants per group, factoring in a 10% expected dropout rate. Conclusions: This study will provide valuable insights into the efficacy and safety of sitafloxacin- versus moxifloxacin-based sequential therapy in treating Mgenitalium infections. These findings have the potential to influence clinical guidelines, favoring more effective therapeutic choices. The multicenter approach enhances the robustness of this study. However, a limitation is the potential insufficiency of statistical power to detect posttreatment-resistant mutant strains in each group, rendering posttreatment-resistance mutations a notable concern. In the future, we may need to increase the sample size to enhance power. Trial Registration: Japan Registry of Clinical Trials (jRCTs031230111); https://jrct.niph.go.jp/en-latest-detail/jRCTs031230111 International Registered Report Identifier (IRRID): DERR1-10.2196/52565


  • Open Access

    Sitafloxacin- Versus Moxifloxacin-Based Sequential Treatment for Mycoplasma Genitalium Infections: Protocol for a Multicenter, Open-Label Randomized Controlled Trial (Preprint)

    by Naokatsu Ando, Daisuke Mizushima, Yosuke Shimizu, Yukari Uemura, Misao Takano, Morika Mitobe, Kai Kobayashi, Hiroaki Kubota, Hirofumi Miyake, Jun Suzuki, et al.

    BACKGROUND Mycoplasma genitalium is an emerging sexually transmitted pathogen associated with increasing antibiotic resistance. The current treatment guidelines recommend moxifloxacin-sequential therapy for macrolide-resistant M genitalium or strains with unknown resistance profiles. However, it is unclear whether sitafloxacin, a 4th-generation fluoroquinolone antibiotic, is effective against resistant strains. OBJECTIVE This study aims to assess and compare the efficacy and safety of sitafloxacin- and moxifloxacin-based treatment regimens for managing M genitalium infections. METHODS We will conduct this randomized controlled trial at multiple centers in Japan. Eligible participants include adults aged 18 years or older with a confirmed M genitalium infection, as determined through the nucleic acid amplification test. Patients will be randomly assigned using a stratified approach based on the treatment facility and infection site. The interventions comprise oral sitafloxacin (200 mg) daily for 7 days (with optional pretreatment of oral doxycycline, 200 mg, daily for up to 7 days), with a control group receiving oral doxycycline (200 mg) daily for 7 days followed by moxifloxacin (400 mg) daily for another 7 days. The primary outcome is the treatment success rate with a superiority margin of 10%, as confirmed through the nucleic acid amplification test. Secondary outcomes encompass changes in the bacterial load at the urogenital or rectal sites and the emergence of posttreatment-resistant mutant strains. RESULTS Enrollment commenced in June 2023 and will conclude in December 2024, with findings anticipated by 2025. The expected success rates fall within the range of 80% for sitafloxacin and 42% for moxifloxacin against M genitalium carrying the G248T (S83I) mutation, based on previous studies. Accordingly, with a 5% significance level (2-sided) and 80% statistical power, we aim to recruit 50 participants per group, factoring in a 10% expected dropout rate. CONCLUSIONS This study will provide valuable insights into the efficacy and safety of sitafloxacin- versus moxifloxacin-based sequential therapy in treating M genitalium infections. These findings have the potential to influence clinical guidelines, favoring more effective therapeutic choices. The multicenter approach enhances the robustness of this study. However, a limitation is the potential insufficiency of statistical power to detect posttreatment-resistant mutant strains in each group, rendering posttreatment-resistance mutations a notable concern. In the future, we may need to increase the sample size to enhance power. CLINICALTRIAL Japan Registry of Clinical Trials (jRCTs031230111); https://jrct.niph.go.jp/en-latest-detail/jRCTs031230111 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/52565

  • Open Access

    Clinical Effectiveness of Sitafloxacin Monotherapy for Treating Rectal and Urogenital Mycoplasma Genitalium Infections in a Setting with a High Prevalence of Quinolone Resistance-Associated Mutations: A Single Center, Prospective Cohort Study

    by Naokatsu Ando, Daisuke Mizushima, Misao Takano, Morika Mitobe, Kai Kobayashi, Hiroaki Kubota, Hirofumi Miyake, Jun Suzuki, Kenji Sadamasu, Takahiro Aoki, et al.

    Background: Mycoplasma Genitalium is sexually transmitted infection with a tendency to develop macrolide and quinolone resistance over time. Methods: This open-label, prospective cohort study was conducted in National Center for Global Health and Medicine, Tokyo, Japan between January 1, 2019, and August 31, 2022. Patients diagnosed with M. genitalium infections using rectal swab or urine sample were included. The patients were administered sitafloxacin 200 mg daily for 7 days. Resistance-associated mutations in ParC, GyrA, and 23S-rRNA were examined. Results: In total, 180 cases were included in this study (Median age, 35 years; interquartile range [IQR], 29–42 years). The time to test of cure was 21 days (IQR, 21–28 days). In total, 77·0% (97/126) harbored mutations, of which 71·4% (90/126) were G248T(S83I), were detected in ParC, and 22·5% (27/120) in GyrA. Overall, the microbiological cure rate of sitafloxacin against M. genitalium infection was 87·7%. The cure rates for rectal and urogenital infection were 86·6% and 91·9%, respectively. The cure rates for strains carrying each genotype were: 100% for ParC and GyrA wild types, 92·9% for ParC G248T(S83I) and GyrA wild-type, and 41·7% for ParC G248T(S83I) and GyrA with mutations. Conclusion: Sitafloxacin monotherapy was highly effective against rectal and urogenital M. genitalium infections regardless of ParC mutations. However, it had limited effectiveness with combined ParC and GyrA mutations. Sitafloxacin monotherapy can be used as first-line treatment of M. genitalium infections in settings with a high prevalence of ParC (and not GyrA) mutations. Funding: This work was supported by the National Center for Global Health and Medicine [grant numbers 19A1002 and 20A1020] and ViiV Healthcare Supported International Clinical Research [ViiV Ref. 209459]. The authors thank Teruya Katsuji, Kunihisa Tsukada, Junko Tanuma for data collection, and Yoshimi Deguchi and Mikiko Ogata, the study coordinator for their assistance in conducting this study. Declaration of Interest: The authors declare no conflicts of interest. Ethical Approval: This study was approved by the Human Research Ethics Committee of NCGM (NCGM-G-003350-00, NCGM-G-002091-00)